[The Cell Therapy in Traumatic Spinal Cord Injury]
- PMID: 29298002
- DOI: 10.15690/vramn731
[The Cell Therapy in Traumatic Spinal Cord Injury]
Abstract
The opportunities and the most promising ways of using cellular technology in traumatic spinal cord injury are considered in this review. A large number of experimental and clinical studies with the use of different types of cells: embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, Schwann cells, olfactory mucosa cells, and others – was conducted. The use of these types of cells in traumatic spinal cord injury treatment often demonstrated a positive therapeutic effect: the motor and sensory function recovery of the spinal cord. However, some types of cell preparations involve some methodological and ethical problems; some types of cell therapies are ineffective or give rise to side effects. These factors complicate the selection of optimal cell therapy for the traumatic spinal cord injury treatment. The most promising cells seem to be the cells of the olfactory mucosa. Getting the olfactory mucosa is considered to be a feasible and safe procedure for patients. The clinical application of the cells of the olfactory mucosa is effective in motor function recovery due to remyelination and axonal regeneration after spinal cord injury. These cells are tissue-specific and autologous since they can be obtained from a patient with spinal cord injury, and after cultivation, expansion, and directed differentiation they can be transplanted to the same patient. The presented benefits of olfactory mucosa cells open up the possibility for its clinical application in the cell therapy.
Similar articles
-
Combined Preparation of Human Olfactory Ensheathing Cells in the Therapy of Post-Traumatic Cysts of the Spinal Cord.Bull Exp Biol Med. 2020 Aug;169(4):539-543. doi: 10.1007/s10517-020-04925-3. Epub 2020 Sep 10. Bull Exp Biol Med. 2020. PMID: 32910386
-
Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury.Cytotherapy. 2013 Jul;15(7):782-91. doi: 10.1016/j.jcyt.2013.03.012. Cytotherapy. 2013. PMID: 23731761
-
Functional recovery after human umbilical cord blood cells transplantation with brain-derived neutrophic factor into the spinal cord injured rat.Acta Neurochir (Wien). 2005 Sep;147(9):985-92; discussion 992. doi: 10.1007/s00701-005-0538-y. Epub 2005 Jul 11. Acta Neurochir (Wien). 2005. PMID: 16010451
-
Non Pharmacological Strategies to Promote Spinal Cord Regeneration: A View on Some Individual or Combined Approaches.Curr Pharm Des. 2016;22(6):720-7. doi: 10.2174/1381612822666151204001103. Curr Pharm Des. 2016. PMID: 26635267 Review.
-
Disease-specific interventions using cell therapies for spinal cord disease/injury.Handb Clin Neurol. 2024;205:263-282. doi: 10.1016/B978-0-323-90120-8.00007-1. Handb Clin Neurol. 2024. PMID: 39341658 Review.
Cited by
-
Application of a New Gene-Cell Construct Based on the Olfactory Mucosa Escheating Cells Transduced with an Adenoviral Vector Encoding Mature BDNF in the Therapy of Spinal Cord Cysts.Bull Exp Biol Med. 2022 Mar;172(5):617-621. doi: 10.1007/s10517-022-05446-x. Epub 2022 Mar 30. Bull Exp Biol Med. 2022. PMID: 35352253
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical